X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS CIPLA DR. DATSONS LABS/
CIPLA
 
P/E (TTM) x -10.9 40.5 - View Chart
P/BV x 0.2 3.7 4.4% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 DR. DATSONS LABS   CIPLA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
CIPLA
Mar-18
DR. DATSONS LABS/
CIPLA
5-Yr Chart
Click to enlarge
High Rs126663 18.9%   
Low Rs31479 6.5%   
Sales per share (Unadj.) Rs133.0189.0 70.4%  
Earnings per share (Unadj.) Rs0.217.6 0.9%  
Cash flow per share (Unadj.) Rs6.634.0 19.4%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs128.8176.7 72.9%  
Shares outstanding (eoy) m31.66805.12 3.9%   
Bonus/Rights/Conversions FCCBESOP-  
Price / Sales ratio x0.63.0 19.5%   
Avg P/E ratio x516.132.5 1,590.4%  
P/CF ratio (eoy) x11.816.8 70.6%  
Price / Book Value ratio x0.63.2 18.8%  
Dividend payout %017.1 0.0%   
Avg Mkt Cap Rs m2,477459,724 0.5%   
No. of employees `000NA23.6 0.0%   
Total wages/salary Rs m5626,901 0.2%   
Avg. sales/employee Rs ThNM6,446.1-  
Avg. wages/employee Rs ThNM1,139.4-  
Avg. net profit/employee Rs ThNM600.0-  
INCOME DATA
Net Sales Rs m4,211152,193 2.8%  
Other income Rs m793,577 2.2%   
Total revenues Rs m4,289155,769 2.8%   
Gross profit Rs m56928,264 2.0%  
Depreciation Rs m20413,228 1.5%   
Interest Rs m4301,142 37.7%   
Profit before tax Rs m1317,470 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-28 6.5%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m62,501 0.2%   
Profit after tax Rs m514,166 0.0%  
Gross profit margin %13.518.6 72.7%  
Effective tax rate %48.014.3 335.5%   
Net profit margin %0.19.3 1.2%  
BALANCE SHEET DATA
Current assets Rs m6,852108,141 6.3%   
Current liabilities Rs m6,71138,322 17.5%   
Net working cap to sales %3.345.9 7.3%  
Current ratio x1.02.8 36.2%  
Inventory Days Days16197 165.8%  
Debtors Days Days31874 428.0%  
Net fixed assets Rs m3,673109,411 3.4%   
Share capital Rs m3171,610 19.7%   
"Free" reserves Rs m3,761140,682 2.7%   
Net worth Rs m4,078142,292 2.9%   
Long term debt Rs m1,67136,621 4.6%   
Total assets Rs m12,633228,606 5.5%  
Interest coverage x1.016.3 6.3%   
Debt to equity ratio x0.40.3 159.2%  
Sales to assets ratio x0.30.7 50.1%   
Return on assets %3.46.7 51.4%  
Return on equity %0.110.0 1.2%  
Return on capital %7.710.0 77.1%  
Exports to sales %22.932.8 69.9%   
Imports to sales %14.30-   
Exports (fob) Rs m96449,883 1.9%   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96451,691 1.9%   
Fx outflow Rs m60721,033 2.9%   
Net fx Rs m35730,658 1.2%   
CASH FLOW
From Operations Rs m1,34514,628 9.2%  
From Investments Rs m-2,256-8,540 26.4%  
From Financial Activity Rs m-1,200-3,855 31.1%  
Net Cashflow Rs m-2,1112,431 -86.8%  

Share Holding

Indian Promoters % 4.5 16.0 28.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 1.4 23.7 5.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 94.1 26.2 359.2%  
Shareholders   20,807 161,166 12.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare DR. DATSONS LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS